NASDAQ:EXAS
EXACT Sciences Corporation Stock News
$62.07
+1.53 (+2.53%)
At Close: May 03, 2024
Exact Sciences schedules second quarter 2023 earnings call
06:00am, Monday, 10'th Jul 2023
MADISON, Wis., July 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its se
Here's Why You Should Buy Exact Sciences (EXAS) Stock Now
12:15pm, Tuesday, 04'th Jul 2023
Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard growth and raised guidance.
Analysts Think This Soaring Cathie Wood Stock Has Peaked. Are They Right?
09:53am, Wednesday, 28'th Jun 2023
Analysts project Exact Sciences' stock will fall from here. The company has generated strong revenue growth.
Are You Looking for a Top Momentum Pick? Why Exact Sciences (EXAS) is a Great Choice
01:24pm, Friday, 23'rd Jun 2023
Does Exact Sciences (EXAS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Analysts Bullish On Exact Sciences' Advanced Cancer Screening
07:10am, Friday, 23'rd Jun 2023
Exact Sciences Corp. NASDAQ: EXAS is on a self-proclaimed mission to change the way cancer is detected and treated. The Madison, Wisconsin company is among the market's best price performers, advancin
2 Stocks to Invest $500 In and Hold For 10 Years
09:53am, Thursday, 22'nd Jun 2023
Exact Sciences' laudable goal of fighting cancer turns out to be good for investors, too. Pinterest can make headway by integrating e-commerce capabilities into its platform.
Is Exact Sciences (EXAS) Outperforming Other Medical Stocks This Year?
11:04am, Wednesday, 21'st Jun 2023
Here is how Exact Sciences (EXAS) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Exact Sciences shares gain on results from non-invasive cancer screening test
08:18am, Wednesday, 21'st Jun 2023
Shares of Exact Sciences Corp. EXAS, +0.98% gained more than 7% in premarket trading Wednesday after the company released results from a study of its next-generation Cologuard, a non-invasive colorect
Exact Sciences set to rally on positive top-line results from pivotal BLUE-C study
08:14am, Wednesday, 21'st Jun 2023
Exact Sciences (NASDAQ:EXAS) shares rose in Wednesday pre-market trading after the molecular diagnostics company specializing in the detection of early-stage cancers announced positive top-line result
Exact Sciences' shares pop on positive Cologuard trial results
07:12pm, Tuesday, 20'th Jun 2023
Kevin Conroy, Exact Sciences CEO, joins 'Fast Money' to discuss Exact Sciences latest trial results for its colo-rectal cancer tests, Cologuard.
Exact Sciences says its new colon cancer test shows 30% lower false positive rate
04:24pm, Tuesday, 20'th Jun 2023
Exact Sciences said on Tuesday its next-generation screening test for colon cancer showed 30% lower false positive rate for detecting the disease in a study when compared to trial data on its already
3 Revolutionary Companies With Trillion-Dollar Potential
08:01pm, Wednesday, 14'th Jun 2023
Finding early-stage, revolutionary companies whose market capitalizations can reach $1 trillion can be very lucrative. Just look atAlphabet (NASDAQ: GOOG, NASDAQ: GOOGL ), Apple (NASDAQ: AAPL ), and
Why Is Exact Sciences (EXAS) Up 11.5% Since Last Earnings Report?
12:38pm, Thursday, 08'th Jun 2023
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
03:04pm, Wednesday, 07'th Jun 2023
Investors are optimistic about Exact Sciences (EXAS) led by continued strength across the Screening and Precision Oncology businesses.
3 Stocks, 1 Potentially Explosive Growth Theme | June 5, 2023
09:27am, Monday, 05'th Jun 2023
#Morningstar #StockMarket #Investing Plus our take on Nvidia stock and our market outlook for June. Read more from David Sekera here: https://www.morningstar.com/stocks/2-undervalued-medtech-stocks-op
